Upon inhibition of ADORA2B, Wilkat et al. observed a significant decrease in the proliferation of human HNSCC cells, which supports the new therapeutic approach to modulate the ADO pathway [21]. Here, ADORA2B is linked to head and neck squamous cell carcinoma.